References and Supporting Research on Depression

National Mental Health Association: Your local Mental Health Association can put you in touch with community mental health services and self-help support groups. To contact the Mental Health Association where you live call:

The National Mental Health Association Information Center: 800/969-NMHA (6642); or visit www.nmha.org.

The National Mental Health Association offers printed information on a wide variety of mental health disorders and subjects relating to mental health. They also provide a national directory of Mental Health Associations across the country.

National Institute of Mental Health
Science Writing, Press & Dissemination Branch
6001 Executive Boulevard
Room 8184, MSC 9663
Bethesda, MD 20892-9663
Phone: 301-443-4513 or 1-866-615-NIMH (6464) toll-free
TTY: 301-443-8431 or 1-866-415-8051 toll-free
FAX: 301-443-4279
E-mail: [email protected]
Website: http://www.nimh.nih.gov

To find a qualified therapist please contact:

The Academy of Cognitive Therapy

www.academyofct.org

Telephone: 610-664-1273

Association for Behavioral and Cognitive Therapies

www.abct.org

Telephone: 212-647-1890

National Association of Cognitive-Behavioral Therapists

www.nacbt.org

Telephone: 1-800-853-1135

References

  1. Beasley J: The Betrayal of Health. The impact of nutrition, environment, and lifestyle on illness in America. Random House, New York, 1991.
  2. Fielding JE: Smoking: Health effects and control. New Eng J Med 313:491-8, 555-61,1985.
  3. Mattson ME, Pollack ES, and Cullen JW: What are the odds smoking will kill you? Am J Publ Health 77:425-31,1987.
  4. Carroll BJ, Curtis GC, and Mendels J: Cerebrospinal fluid and plasma free cortisol concentra­tions in depression. Psychol Med 6:235-44, 1976.
  5. Altar C, et al: Glucocorticoid induction of tryptorhan oxygenase. Biochem PharmacoI32:979­84, 1983.
  6. Kinsman R and Hood J: Some behavioral effects of ascorbic acid deficiency. Am J Clin Nutr. 24:455-64,1971.
  7. Chou T: Wake up and smell the coffee. Caffeine, coffee, and the medical consequences. West J Med 157:544-53, 1992.
  8. Gilliand K and Bullick W: Caffeme: A potential drug of abuse. Adv Alcohol Subst Abuse 3:53-73, 1984.
  9. Greden J, et al: Anxiety and depression associated with caffeinism among psychiatric patients. Am J. Psychiatry 131: 1089-94, 1979.
  10. Neil JF, et al: Caffeinism complicating hypersomnic depressive disorders. Compr Psychiatry 19:377-85,1978.
  11. Charney D, Henninger G, and Jatlow P: Increased anxiogenic effects of caffeine in panic disor­ders. Arch Gen Psychiatry 42:23343,1984.
  12. Bolton S and Null G: Caffeine, psychological effects, use and abuse. J Orthomol Psychiatry 10:202-11,1981.
  13. Kreitsch K, et al: Prevalence, presenting symptoms, and psychological characteristics of individu­als experiencing a diet-related mood disturbance. Behav Ther 19:593-4, 1985.
  14. Christensen L: Psychological distress and diet-effects of sucrose and caffeine. J ApI Nutr 40:44-50, 1988.
  15. Martin JE and Dubbert PM: Exercise applications and promotion in behavioral medicine. J Consult Clin PsychoI50:1004-17; 1982.
  16. Weyerer S and Kupfer B: Physical exercise and psychological health. Sports Med 17:108-16, 1994.
  17. Daniel Carr, et al: Physical conditioning facilitates the exercise-induced secretion of beta­ endorphin and beta-lipoprotein in women. New Engl J. Med 305:560-5, 1981.
  18. Lobstein D, Mosbacher BJ and Ismail AH: Depression as a powerful discriminator between physically active and sedentary middle-aged med. J Psychosom Res 27:69-76, 1983.
  19. Folins CH and Sime WE: Physical fitness training and mental health. Am Psychologist 36:375-88, 1981.
  20. Martinsen EW: The role of aerobic exercise in the treatment of depression. Stress Med 3:93-100, 1987.
  21. Weyerer S and Kupfer B: Physical exercise and psychological health. Sports Med 17:108-16, 1994. Byrne A and Byrne DG: The effect of exercise on depression, anxiety, and other mood states: a review. J. Psychosom Res. 37:565-74, 1993.
  22. Casper RC: Exercise and mood. World Rev Nutr Diet 71:115-43,1993.
  23. Winokur A, et al: Insulin resistance after glucose tolerance testing in patients with major depression. AmJ Psychiatry 145:325 30,1988.
  24. Wright JH, J acisn JJ, Radin NS, et al: Glucose metabolism in unipolar depression. Br J Psychiatry 132:386-93, 1978.
  25. Hadji-Georgeopoulus A, et al: Elevated hypoglycemic index and late hyperinsulinism in symp­tomatic postprandial hypoglycemia. J Clin Endocrinol MetaboI50:371-6, 1980.
  26. Fabrykant M: The problem of functional hyperinsulinism on functional hypoglycemia attributed to nervous causes. Laboratory and clinical correlations. Metabolism 4: 469-79,1955.
  27. Werbach M: Nutritional Influences on Illness: A Sourcebook of Clinical Research. Third Line Press, Tarzana, CA, 1991.
  28. Stanto JL and Keast DR: Serum cholesterol, fat intake, and breakfast consumption in the U.S. adult population. J Am ColI Nutr 8:567-72,1989.
  29. Crellin R, Botiglieri T, and Reynolds EH: Folates and psychiatric disorders. Clinical potential. Drugs 45:623-36, 1993.
  30. Carney MWP, et al: Red cell folate concentrations in psychiatric patients. J. Affective Disorders 19:207-13,1990.
  31. Godfrey PSA, et al: Enhancement of recovery from psychiatric illness by methyl folate. Lancet 336:392-5,1990.
  32. Reynolds E, et al: Folate deficiency in depressive illness. Br J Psychiat 117:287-92, 1970.
  33. PDR for Herbal Medicines (Medical Economics Company, 2000).
  34. http://articles.cnn.com/2007-07-09/health/antidepressants_1_antidepressants-high-blood-pressure-drugs-psychotropic-drugs?_s=PM:HEALTH
  35. http://www.examiner.com/article/too-many-americans-on-antidepressants
  36. Altshuler LL, Hendrich V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. Journal of Clinical Psychiatry, 1998; 59:29.
  37. http://www.nimh.nih.gov/health/publications/depression/complete-index.shtml
  38. http://www.ehow.com/about_5649169_many-americans-affected-depression_.html
  39. http://www.webmd.com/depression/guide/depression
  40. Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA, Schlernitzauer MA, Whyte EM, Gildengers A, Karp J, Lenze E, Szanto K, Bensasi S, Kupfer DJ. Maintenance treatment of major depression in old age. New England Journal of Medicine, 2006 Mar 16; 354(11):1130–1138.
  41. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. Treatment for Adolescents with Depression Study (TADS) team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association, 2004; 292(7):807–820.
  42. Endocrine Society’s 92nd Annual Meeting. June 19-22, 2010.
  43. Stull AJ, Cash KC, Johnson WD, Champagne CM, Cefalu WT. Bioatives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women. J Nutr 2010 Oct;140(10):1764-8.
  44. Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31:16-21.
  45. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John’s wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999;290:1363-8.
  46. Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001;68:1593-605.
  47. Vormfelde SV, Poser W. Hyperforin in extracts of St. John’s wort (Hypericum perforatum) for depression [letter]. Arch Intern Med 2000;160:2548-9.
  48. Schule C, Baghai T, Ferrera A, Laakmann G. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 2001;34:S127-33.
  49. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001;158:289-94.
  50. Knaudt PR, Connor KM, Weisler RH, et al. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999;187:692-5.
  51. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD- 10. Pharmacopsychiatry 1997;30:81-5.
  52. Wheatley D. LI 160, an extract of St. John’s wort, versus amitriptyline in mildly to moderately depressed outpatients – a controlled 6-week clinical trial. Pharmacopsychiatry 1997;30:77-80
  53. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients – an overview. Pharmacopsychiatry 1997;30 Suppl 2:72-6.
  54. Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. J Geriatr Psychiatry Neurol 1994;7 Suppl 1:S12-4.
  55. Kim HL, Streltzer J, Goebert D. St. John’s wort for depression: A meta analysis of well-defined clinical trials. J Nerv Ment Dis 1999;187:532-9.
  56. Linde K, Ramirez G, Mulrow CD, et al. St. John’s wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-8.
  57. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John’s wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289-96.
  58. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized multicentre study of treatment for eight weeks. BMJ 1999;319:1534-9.
  59. Gaster B, Holroyd J. St John’s wort for depression. Arch Intern Med 2000;160:152-6.
  60. Schrader E. Equivalence of St. John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15:61-8.
  61. Linde K, Mulrow CD. St. John’s wort for depression. Cochrane Database Syst Rev 2000;(2):CD000448.
  62. Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther 2000;22:411-9.
  63. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 2000;132:743-56.
  64. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berl) 2002;164:301-8.
  65. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005;330:503.
  66. Linde K, Mulrow CD, Berner M, Egger M. St John’s Wort for depression. Cochrane Database Syst Rev 2005;(3):CD000448.
  67. Woelk H. Comparison of St. John’s wort and imipramine for treating depression: randomized controlled trial. BMJ 2000;321:536-9.
  68. Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002;59:592-6.
  69. u KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71.
  70. Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91.
  71. Tiemeier H, van Tuijl HR, Hofman A, et al. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 2003;78:40-6.
  72. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-9.
  73. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71.
  74. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9.
  75. FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://vm.cfsan.fda.gov/~dms/ds-ltr11.html.
  76. Pedersen HS, Mulvad G, Seidelin KN, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-3.
  77. Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 1998;5:257-61.
  78. Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst Rev 2003;(2):CD003390.
  79. Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 1989;16:103-7.
  80. Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32.
  81. Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003;23:309-13.
  82. Tiemeier H, van Tuijl HR, Hofman A, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099-101.
  83. Morris MS, Fava M, Jacques PF, et al. Depression and folate status in the US Population. Psychother Psychosom 2003;72:80-7.
  84. Tolmunen T, Voutilainen S, Hintikka J, et al. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. J Nutr 2003;133:3233-6.
  85. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Dis 2000;60:121-31.
  86. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-5.
  87. Benjamin J, Agam G, Levine J, et al. Inositol treatment in psychiatry. Psychopharmacol Bull 1995;31:167-75.
  88. Allan SJ, Kavanagh GM, Herd RM, Savin JA. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. Br J Dermatol 2004;150:966-9.
  89. Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. Isr J Psychiatry Relat Sci 1995;32:14-21.
  90. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792-4.
  91. Young SN. How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci 2007;32(6):394-9.
  92. Jacobs BL, Fornal CA. Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 1999;21:9S-15S.
  93. Rueter LE, Jacobs BL. A microdialysis examination of serotonin release in the rat forebrain induced by behavioral/environmental manipulations. Brain Res 1996;739:57-69.
  94. Chaouloff F, Laude D, Guezennec Y, et al. Motor activity increases tryptophan, 5-hydroxyindoleacetic acid, and homovanillic acid in ventricular cerebrospinal fluid of the conscious rat. J Neurochem 1986;46:1313-6.
  95. Norris DO, Luckman D. A new twist on mental health. Personal Fitness Professional 2004 Jan;28-31.
  96. Rao ML, Müller-Oerlinghausen B, Mackert A, Strebel B, Stieglitz RD, Volz HP. Blood serotonin, serum melatonin and light therapy in healthy subjects and in patients with nonseasonal depression. Acta Psychiatr Scand. 1992 Aug;86(2):127-32.
  97. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and metaanalysis of the evidence. Am J Psychiatry 2005;162:656-62.
  98. Lam RW, Carter D, Misri S, et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiattry Res 1999;86:185-92.
  99. Epperson CN, Terman M, Terman JS, et al. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. J Clin Psychiatry 2004;65:421-5.
  100. Carlsson A, Svennerholm L, Winblad B. Seasonal and circadian monoamine veriations in human brains examined post mortem. Acta Psychiatr Scand Suppl 1980;280:75-85.
  101. Lambert GW, Ried C, Kaye DM, et al. Effects of sunlight and season on serotonin turnover in the brain. Lancet 2002;360:1840-2.
  102. Ferraro JS, Steger RW. Diurnal variations in brain serotonin are driven by the photic cycle and are not ciracidan in nature. Brain Res 1990;512:121-4.
  103. Cagampang RRA, Yamazaki S, Otori Y, et al. Serotonin in the raphe nuclei: regulation by light and an endogenous pacemaker. Neuroreport 1993;5:49-52.
  104. aan het Rot M, Benkelfat C, Boivin DB, et al. Bright light exposure during acute tryptophan depletion prevents a lowering of mood in mildly seasonal women. Eur Neuropsychopharmacol. Epub 2007 Jun 18 ahead of print.
  105. Lansdowne, A. T., and S. C. Provost. Vitamin D3 Enhances Mood in Healthy Subjects During Winter. Psychopharmacology (Berl) 135, no. 4 (1998): 319-23.
  106. Gloth FM 3rd, Alam W, Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging. 1999;3(1):5-7.
  107. Johnson RA, Ruhl JM. Living Your Unlived Life. Penguin Group, New York. 2009.

Contact Us

Call us at 866-888-6721

Email us

Connect with Us

Our Facebook and Twitter pages are constantly being updated with helpful information on healthy living.